Zahed Subhan has 26 years experience in the pharmaceutical and biotechnology industries spanning roles in research, clinical development, sales, marketing and business development, including managerial positions with Sanofi-Synthelabo, Glaxo Wellcome, Merck, the Dupont-Merck Pharmaceutical Company (now part of Bristol-Myers Squibb), Gemini Genomics (acquired by Sequenom Inc) and Locus Pharmaceuticals. Zahed was also previously Chief Executive Officer of Nuevolution A/S based in Copenhagen, Denmark and is a co-founder of Marillion Pharmaceuticals.

During his career, Dr. Subhan has been instrumental in establishing more than 30 collaborations and co-operative agreements with major pharmaceutical and biotech companies, including licensing, co-marketing, co-promotion and acquisition transactions valued in excess of $600MM. He has also been responsible for the successful launches of flagship drugs, including Imitrex®, Celexa®, Prinivil®/Zestril®, Sinemet CR® and Viazem®/Tiazac®, in major markets.

Dr. Subhan holds a BS in Pharmacology from the University of Sunderland, School of Pharmacy, an MS in Applied Psychology & Neuroscience from the University of Aston, a PhD in Pharmacology from the University of Leeds, an MBA from the University of Bradford and an LLB (Law) degree from Thames Valley University, London.

SCIENTIFIC ADVISORS:
Richard Wahl, MD
(Director of Nuclear Medicine, John Hopkins University, Baltimore, MD

Professor Michael Tweedle, PhD
(Chair, Radiology, Ohio State University; Former President & CEO of Bracco Research USA & co-inventor of Lu-AMBA)

Dan Shochat, PhD
(Kalabios Inc; Formerly Coulter Pharmaceuticals;
Lead development role in Bexxar®)